NTLA-6001 / Intellia Therap - LARVOL DELTA

Intellia Therapeutics Highlights Strategic Priorities and Anticipated 2023 Key Milestones (GlobeNewswire) - "Ex Vivo Programs - NTLA-6001 for CD30+ Lymphomas: Identify collaboration opportunities to advance development of NTLA-6001. Additional ex vivo candidates: Advance multiple programs, wholly owned or in collaboration with partners, utilizing allogeneic platform."

Preclinical • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

Intellia Therapeutics Announces First Quarter 2022 Financial Results and Highlights Recent Company Progress (GlobeNewswire) - "Intellia is initiating IND-enabling activities for NTLA-6001. At the 2022 Keystone Symposia’s Precision Genome Engineering Conference, Intellia presented preclinical data leading to the development of NTLA-6001....NTLA-5001 for AML: Continue to enroll patients in Phase 1/2a study in 2022."

Enrollment status • Acute Myelogenous Leukemia • Hematological Malignancies • Hodgkin Lymphoma • Oncology

Intellia Therapeutics Presents Preclinical Data Demonstrating Advancements in its CRISPR-Engineered Allogeneic Platform at the 2022 Keystone Symposia’s Precision Genome Engineering Conference (GlobeNewswire) - "The data shared at Keystone demonstrated that Intellia’s proprietary allogeneic solution created T cells that not only avoided immune recognition by host CD4 and CD8 T cells, but also were protected from NK cell-mediated killing in in vitro and in vivo mouse models. Furthermore, allogeneic T cells engineered sequentially with LNPs retained high viability, cell expansion, memory phenotype, cytotoxic and cytokine secretion characteristics. Intellia’s allogeneic platform can be deployed for TCR-T and CAR-T cell therapy. As part of these platform advancement efforts, Intellia evaluated multiple CD30 CAR constructs in a series of in vitro and in vivo experiments. The most potent CAR construct showed complete tumor regression and protection from tumor rechallenge in a T cell lymphoma model."

Preclinical • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2021 Financial Results and Highlights Recent Company Progress (GlobeNewswire) - "...Intellia announced the nomination of its first ex vivo allogeneic development candidate, NTLA-6001, for CD30-expressing hematologic cancers, including cHL. NTLA-6001 is developed using Intellia’s proprietary allogeneic cell engineering platform, which leverages a novel combination of sequential gene edits. Preclinical data presented on its differentiated allogeneic engineering platform showed allogeneic T cells were shielded from immune rejection, both host T and natural killer (NK) cell attack....Intellia is advancing towards IND-enabling activities and plans to present preclinical data leading to the development of NTLA-6001 at an upcoming scientific conference in 2022."

Pipeline update • Preclinical • Hematological Malignancies • Hodgkin Lymphoma • Oncology